FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367304854> ?p ?o ?g. }

• W4367304854 abstract "<h3>Objective:</h3> To evaluate if oral anticoagulant therapy change (OAC change) or adding antiplatelet therapy to anticoagulation (AC+AP) in patients with nonvalvular atrial fibrillation (AF) and acute ischemic stroke (AIS) or transient ischemic attack (TIA) despite OAC compliance, is associated with lower risk of recurrent cerebrovascular events compared to patients that continued the same anticoagulant regimen. <h3>Background:</h3> Patients with AF still have an appreciable risk of AIS or TIA despite compliance with OAC. Yet little is known about the best management options in this population. <h3>Design/Methods:</h3> We reviewed all consecutive patients with AF on OAC that presented with AIS/TIA to our tertiary academic stroke center between 2011–2021. Baseline characteristics, type of index event, antithrombotic therapy before and after index event, subsequent recurrent AIS/TIA or major bleeding events were extracted. Fisher’s exact or Log-rank tests and logistic regression models were used to compare outcomes between OAC unchange vs OAC change, and AC+AP vs AC only groups. <h3>Results:</h3> 185 patients (mean age 78.3 ± 12 years) were included. 61% were males and 79 (42.7%) had AIS at index event. 17 (9%) had OAC change and 100 (79%) received AP+AC. 39 (21.15%) had recurrent AIS/TIA, and 28 (15.1%) had major bleeding following the index event. No significant difference was observed between OAC unchange versus OAC change groups regarding recurrent AIS/TIA (HR = 0.607, 95% CI: 0.229–1.609, p = 0.316) or major bleeding events (OR = 1.541, 95% CI: 0.391–10.299, p = 0.586). Additionally, no significant difference was observed between AC+AP versus AC groups regarding recurrent AIS/TIA (HR= 0.863, 95% CI: 0.430–1.732, p = 0.679) or major bleeding events (OR= 0.894, 95% CI: 0.377–2.135, p = 0.798). <h3>Conclusions:</h3> In patients with AF and acute ischemic cerebrovascular events despite OAC compliance, changing anticoagulant or adding antiplatelet agent may not decrease risk of future cerebrovascular events. <b>Disclosure:</b> Dr. Harahsheh has nothing to disclose. Mr. Elshaigi has nothing to disclose. Dr. Alhayek has nothing to disclose. Vanesa Vanderhye has nothing to disclose. Dr. O’Carroll has nothing to disclose. Dr. Dumitrascu has nothing to disclose." @default.
• W4367304854 created "2023-04-29" @default.
• W4367304854 creator A5010575841 @default.
• W4367304854 creator A5021905278 @default.
• W4367304854 creator A5025364822 @default.
• W4367304854 creator A5076849200 @default.
• W4367304854 creator A5081700572 @default.
• W4367304854 creator A5089626904 @default.
• W4367304854 date "2023-04-25" @default.
• W4367304854 modified "2023-10-17" @default.
• W4367304854 title "Managing Recurrent Ischemic Cerebrovascular Events in Patients with Atrial Fibrillation Compliant with Oral Anticoagulant Therapy (P6-5.001)" @default.
• W4367304854 doi "https://doi.org/10.1212/wnl.0000000000203403" @default.
• W4367304854 hasPublicationYear "2023" @default.
• W4367304854 type Work @default.
• W4367304854 citedByCount "0" @default.
• W4367304854 crossrefType "proceedings-article" @default.
• W4367304854 hasAuthorship W4367304854A5010575841 @default.
• W4367304854 hasAuthorship W4367304854A5021905278 @default.
• W4367304854 hasAuthorship W4367304854A5025364822 @default.
• W4367304854 hasAuthorship W4367304854A5076849200 @default.
• W4367304854 hasAuthorship W4367304854A5081700572 @default.
• W4367304854 hasAuthorship W4367304854A5089626904 @default.
• W4367304854 hasConcept C126322002 @default.
• W4367304854 hasConcept C127413603 @default.
• W4367304854 hasConcept C164705383 @default.
• W4367304854 hasConcept C2777015399 @default.
• W4367304854 hasConcept C2778205648 @default.
• W4367304854 hasConcept C2779161974 @default.
• W4367304854 hasConcept C2780645631 @default.
• W4367304854 hasConcept C2781413609 @default.
• W4367304854 hasConcept C2908647359 @default.
• W4367304854 hasConcept C71924100 @default.
• W4367304854 hasConcept C78519656 @default.
• W4367304854 hasConcept C99454951 @default.
• W4367304854 hasConceptScore W4367304854C126322002 @default.
• W4367304854 hasConceptScore W4367304854C127413603 @default.
• W4367304854 hasConceptScore W4367304854C164705383 @default.
• W4367304854 hasConceptScore W4367304854C2777015399 @default.
• W4367304854 hasConceptScore W4367304854C2778205648 @default.
• W4367304854 hasConceptScore W4367304854C2779161974 @default.
• W4367304854 hasConceptScore W4367304854C2780645631 @default.
• W4367304854 hasConceptScore W4367304854C2781413609 @default.
• W4367304854 hasConceptScore W4367304854C2908647359 @default.
• W4367304854 hasConceptScore W4367304854C71924100 @default.
• W4367304854 hasConceptScore W4367304854C78519656 @default.
• W4367304854 hasConceptScore W4367304854C99454951 @default.
• W4367304854 hasLocation W43673048541 @default.
• W4367304854 hasOpenAccess W4367304854 @default.
• W4367304854 hasPrimaryLocation W43673048541 @default.
• W4367304854 hasRelatedWork W115756687 @default.
• W4367304854 hasRelatedWork W200527163 @default.
• W4367304854 hasRelatedWork W2038817894 @default.
• W4367304854 hasRelatedWork W2042801381 @default.
• W4367304854 hasRelatedWork W2111666164 @default.
• W4367304854 hasRelatedWork W2402713911 @default.
• W4367304854 hasRelatedWork W2410698956 @default.
• W4367304854 hasRelatedWork W3014516826 @default.
• W4367304854 hasRelatedWork W3029086206 @default.
• W4367304854 hasRelatedWork W4248905858 @default.
• W4367304854 isParatext "false" @default.
• W4367304854 isRetracted "false" @default.
• W4367304854 workType "article" @default.